1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
FEATURED COMPANIES
- Eisai
- GlaxoSmithKline
- GW Pharmaceuticals
- Pfizer
- UCB
1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
The emergence of biomarkers to gain traction in the market. The world of epilepsy diagnostics is experiencing a trend of emerging biomarkers for epileptogenesis. Epilepsy is the disorder of repeated seizures; hence, these biomarkers for epileptogenesis are used to identify the spontaneity of the seizures. The analysts have predicted that the pediatric epilepsy therapeutics market will register a CAGR of close to 6% by 2023.
Market Overview
Increasing demand for second and third-generation AEDs
The global pediatric epilepsy therapeutics market is witnessing a surge in the number of second-generation AEDs such as felbamate, lamotrigine, as they have low interaction and propensity for cognitive side-effects.
Adverse side effects and increasing social stigma
The global pediatric epilepsy therapeutics market has many approved drugs; however, they are associated with major side effects.
For the detailed list of factors that will drive and challenge the growth of the pediatric epilepsy therapeutics market during the 2019-2023, view this report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Eisai and GlaxoSmithKline the competitive environment is quite intense. Factors such as the emergence of biomarkers and the increasing demand for second and third-generation AEDs, will provide considerable growth opportunities to pediatric epilepsy therapeutics manufactures. Eisai, GlaxoSmithKline, Pfizer, UCB, and GW Pharmaceuticals are some of the major companies covered in this report.
‘With the presence of a considerable number of companies, this market appears to be fragmented. Some of the leading pediatric epilepsy therapeutic companies are forming alliances with organizations and vendors to develop therapeutics that a novel mechanism to make a smoother market entry.’
Market Overview
Increasing demand for second and third-generation AEDs
The global pediatric epilepsy therapeutics market is witnessing a surge in the number of second-generation AEDs such as felbamate, lamotrigine, as they have low interaction and propensity for cognitive side-effects.
Adverse side effects and increasing social stigma
The global pediatric epilepsy therapeutics market has many approved drugs; however, they are associated with major side effects.
For the detailed list of factors that will drive and challenge the growth of the pediatric epilepsy therapeutics market during the 2019-2023, view this report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Eisai and GlaxoSmithKline the competitive environment is quite intense. Factors such as the emergence of biomarkers and the increasing demand for second and third-generation AEDs, will provide considerable growth opportunities to pediatric epilepsy therapeutics manufactures. Eisai, GlaxoSmithKline, Pfizer, UCB, and GW Pharmaceuticals are some of the major companies covered in this report.
‘With the presence of a considerable number of companies, this market appears to be fragmented. Some of the leading pediatric epilepsy therapeutic companies are forming alliances with organizations and vendors to develop therapeutics that a novel mechanism to make a smoother market entry.’
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Eisai
- GlaxoSmithKline
- GW Pharmaceuticals
- Pfizer
- UCB
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORTPART 07: CUSTOMER LANDSCAPEPART 09: DECISION FRAMEWORKPART 11: MARKET TRENDS
PART 03: MARKET LANDSCAPE
PART 05: FIVE FORCES ANALYSIS
PART 06: MARKET SEGMENTATION BY PRODUCT
PART 08: GEOGRAPHIC LANDSCAPE
PART 10: DRIVERS AND CHALLENGES
PART 12: VENDOR LANDSCAPE
PART 13: VENDOR ANALYSIS
PART 14: APPENDIX
List of Exhibits
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- Eisai
- GlaxoSmithKline
- GW Pharmaceuticals
- Pfizer
- UCB
Global Pediatric Epilepsy Therapeutics Market 2018-2022
The author of the report recognizes the following companies as the key players in the global pediatric epilepsy therapeutics market: Eisai, GlaxoSmithKline, Pfizer, UCB, and GW Pharmaceuticals.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the emergence of biomarkers.”
According to the report, one of the major drivers for this market is the increasing demand for second and third-generation AEDs.
Further, the report states that one of the major factors hindering the growth of this market is the adverse side effects and increasing social stigma.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
The author of the report recognizes the following companies as the key players in the global pediatric epilepsy therapeutics market: Eisai, GlaxoSmithKline, Pfizer, UCB, and GW Pharmaceuticals.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the emergence of biomarkers.”
According to the report, one of the major drivers for this market is the increasing demand for second and third-generation AEDs.
Further, the report states that one of the major factors hindering the growth of this market is the adverse side effects and increasing social stigma.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
A selection of companies mentioned in this report includes:
- Eisai
- GlaxoSmithKline
- GW Pharmaceuticals
- Pfizer
- UCB
Note: Product cover images may vary from those shown
